Video Experimental Relacionado
Updated: Sep 10, 2025
09:04
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
672
Nuevos agentes inmunomoduladores en el tratamiento del cáncer de pulmón de células no pequeñas
1Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA. amareyes@coh.org.
Cancer treatment and research
|August 23, 2025
Resumen
Los inhibidores del punto de control inmunológico han transformado el tratamiento del cáncer de pulmón de células no pequeñas (CPNPC). La investigación está en curso para superar la resistencia al tratamiento con nuevas inmunoterapias y estrategias de combinación para mejorar la supervivencia del paciente.
Área de la Ciencia:
- En el campo de la oncología
- Inmunología
- Investigaciones médicas
Sus antecedentes:
- El cáncer de pulmón es la principal causa de mortalidad por cáncer en todo el mundo.
- El cáncer de pulmón de células no pequeñas (CPNP) constituye la mayoría de los casos de cáncer de pulmón.
- La inmunoterapia ha revolucionado el tratamiento del NSCLC, mejorando los resultados y la supervivencia de los pacientes.
Objetivo del estudio:
- Revisar el impacto de los inhibidores del punto de control inmune (ICI) en el tratamiento del NSCLC.
- Explorar estrategias para superar la resistencia primaria y secundaria a la inmunoterapia.
- Discutir nuevos agentes inmunomoduladores y terapias combinadas en desarrollo para el CPNM.
Principales métodos:
- Revisión de la literatura actual sobre la inmunoterapia para el NSCLC.
- Análisis de la eficacia de los inhibidores del punto de control inmunológico (ICI).
- Exploración de estrategias terapéuticas emergentes, incluidos los tratamientos combinados y los agentes novedosos.
Principales resultados:
- Los inhibidores del punto de control inmune (ICI) son altamente eficaces en el NSCLC mutado no controlador.
- La resistencia al tratamiento sigue siendo un desafío importante en el NSCLC.
- Las terapias combinadas son prometedoras, mientras que otros agentes novedosos se encuentran en fase inicial de desarrollo.
Conclusiones:
- La inmunoterapia es una piedra angular del tratamiento moderno del NSCLC.
- La superación de la resistencia a través de estrategias de combinación y agentes novedosos es crucial para un mayor progreso.
- La investigación y el desarrollo continuos de agentes inmunomoduladores son esenciales para avanzar en el tratamiento del NSCLC.
Palabras clave:
Conjugados de anticuerpos y medicamentosLas terapias celularesInhibidores de los puntos de controlInmunoterapia combinadaVacunas contra el neoantígenoPD-L1 y sus derivadosMás Videos Relacionados
Videos de Conceptos Relacionados
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
463
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
463
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K